Jobs's VC Fund Targets Non-Lethal Cancer

Investor and founder of venture firm Yosemite, Jobs, is pursuing the precise goal of making cancer non-lethal. He draws a parallel to AIDS, which has become less deadly in the U.S. due to effective drug cocktails.

Yosemite has successfully closed its second fund with $350 million, a significant increase from its first close. This capital will support both early-stage startup investments, aiming for venture-scale returns, and provide philanthropic grants to scientists.

The firm's unique approach allows for testing new ideas cheaply and quickly in academic settings. This philanthropic arm helps identify promising avenues before significant resources are committed, mitigating the risks inherent in the slow-moving biotech industry.

Yosemite's prior investments include AI drug discovery, cancer screening, and therapeutic medicine startups, reflecting a belief in a consortium of efforts rather than a single solution to make cancer non-lethal.

Jobs acknowledges this is a lifelong endeavor, inspired by his father's legacy, with the ultimate aim of achieving victory over cancer-related death.